$3.9 M

ORPN Mkt cap, 12-Feb-2019
Bioblast Pharma Net income (FY, 2017)-5.9 M
Bioblast Pharma EBIT (FY, 2017)-6 M
Bioblast Pharma Cash, 31-Dec-20173.5 M

Bioblast Pharma Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Sales and marketing expense

829.0k1.1m479.0k

R&D expense

7.7m8.9m2.5m

General and administrative expense

7.0m5.9m3.0m

Operating expense total

15.5m15.9m6.0m

EBIT

(15.5m)(15.9m)(6.0m)

Interest income

135.0k60.0k38.0k

Pre tax profit

(15.3m)(15.8m)(5.9m)

Income tax expense

24.0k216.0k28.0k

Net Income

(15.4m)(16.0m)(5.9m)

Bioblast Pharma Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

7.3m6.9m3.5m

Prepaid Expenses

1.1m663.0k96.0k

Current Assets

20.4m10.5m3.6m

PP&E

91.0k71.0k

Total Assets

20.5m10.6m3.6m

Accounts Payable

1.4m700.0k19.0k

Current Liabilities

2.5m1.9m460.0k

Non-Current Liabilities

70.0k

Total Liabilities

2.6m1.9m460.0k

Common Stock

39.0k45.0k45.0k

Additional Paid-in Capital

41.7m48.5m48.9m

Retained Earnings

(23.8m)(39.8m)(45.8m)

Total Equity

17.9m8.7m3.2m

Financial Leverage

1.1 x1.2 x1.1 x

Bioblast Pharma Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(15.4m)(16.0m)(5.9m)

Depreciation and Amortization

17.0k38.0k64.0k

Accounts Receivable

(786.0k)399.0k567.0k

Accounts Payable

107.0k129.0k(790.0k)

Cash From Operating Activities

(13.2m)(15.5m)(6.4m)

Purchases of PP&E

(48.0k)(18.0k)(2.0k)

Cash From Investing Activities

10.0m9.0m3.0m

Cash From Financing Activities

6.1m

Net Change in Cash

(3.3m)(415.0k)(3.3m)

Interest Paid

162.0k120.0k43.0k

Income Taxes Paid

4.0k210.0k32.0k

Bioblast Pharma Ratios

USDY, 2017

Financial Leverage

1.1 x
Report incorrect company information